Teplinovivint |
| Catalog No.GC62394 |
Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1428064-91-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research[1].
Teplinovivint (compound 175; 0.0003-10 μM) inhibits Wnt/p-catenin activity in human colorectal cancecell line (SW480) in a dose-dependent manner (EC50=152.9 nM)[1]. Teplinovivint inhibits SW480 cells (EC50=25 nM) and primary human mesenchymal stem cells (hMSCs; EC50=10.377 μM)[1]. Teplinovivint (5.8, 10.8, 21.7, 41.7, 83.3, 166.6, 333.3, 750 nM) induced the expression of SCXA, TenacinC and Tenomodulin, in a dose-dependent manner with an EC50 between 139-189 nM[1].
Teplinovivint (compound 175; 10 mg/ml; once daily for 21 days via topical application) causes amelioration of inflammation as well as tendon degeneration. Teplinovivint results in a decrease of aninflammatory plasma biomarker, KC/GRO in the Collagenase-induced Tendon Injury Model[1]. Teplinovivint (1 mg/ml with 1% BA) has a Tmax of 1 hours in plasma[1].
[1]. Vishal DESHMUKH, et al. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. WO2018075858A1.
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *